TerminatedPHASE2, PHASE3NCT02790034

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Studying Rett syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Newron Pharmaceuticals SPA
Principal Investigator
Ravi Anand, MD, MD
Newron Pharmaceuticals
Intervention
Sarizotan low dose(drug)
Enrollment
129 enrolled
Eligibility
4 years · All sexes
Timeline
20162020

Study locations (14)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02790034 on ClinicalTrials.gov

Other trials for Rett syndrome

Additional recruiting or active studies for the same condition.

See all trials for Rett syndrome

← Back to all trials